20-Year study aims to unlock secrets of schizophrenia recovery
NCT ID NCT07616999
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study follows 178 people who had a first episode of psychosis to see how early treatment choices and relapses affect their thinking, daily life, and mental health over 20 years. Participants attend one interview to assess symptoms, thinking skills, and functioning. The goal is to learn what leads to better long-term outcomes.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- What this could lead to
- If successful, this study could reveal which early treatment strategies lead to better long-term outcomes for people with schizophrenia.
- What could go wrong
- This is an observational follow-up, not a treatment trial. It may not prove cause and effect, and results may not apply to all patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 178 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
May 2026
- Expected to finish
-
Dec 2028
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Trained research assistants will approach active patients at their upcoming psychiatric out-patient consultations at the hospitals to introduce the follow-up study and to obtain written informed consent.
- Ages
-
18 to 65 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Participants were individuals who previously participated in a randomized controlled trial investigating medication continuation/discontinuation on relapse during first episode psychosis (ClinicalTrials.gov NCT00334035). The trial included specific inclusion and exclusion criteria, detailed as follows: Inclusion Criteria: * A diagnosis of schizophrenia or non-affective psychosis (schizophreniform disorder, schizoaffective disorder, brief psychotic disorder, or psychosis not otherwise specified) (DSM-IV) * Aged 18 to 65 years at the time of original enrolment * Had been treated with antipsychotic drugs for at least 12 months * No history of relapse or exacerbation or had to be asymptomatic (free of positive symptoms of psychosis) at study entry. Exclusion Criteria: * A diagnosis of drug-induced psychosis * Current treatment with clozapine, with mood stabilizing medications (lithium, valproate or carbamazepine) or with depot medication * Had high risk of suicide or violence * Inability to provide informed consent at recruitment
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Psychosis not otherwise specified are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Department of Psychiatry, Queen Mary Hospital
RECRUITINGHong Kong, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Scientists probe brain's reward system in mental illness
- New schizophrenia drug targets brain glutamate, not dopamine
- New drug candidate takes aim at schizophrenia symptoms
- New schizophrenia drug goes Head-to-Head with standard antipsychotics in Long-Term trial
- Five-Year safety check for experimental schizophrenia drug
- A shot every few weeks? new drug tested for schizophrenia